Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Reminyl Side Effects Lawsuits | Side Effects: Heart Attacks, Strokes

Reminyl Side Effects May Lead To Heart Attacks Lawsuits

Reminyl | Lawsuits, Lawyers | Side Effects: Heart Attacks, Strokes

Data from two clinical trials indicated that people taking Reminyl (Generic: Galantamine) have a much higher death rate than those taking a placebo. Reminyl is an Alzheimer's disease drug. The review was announced on 1/21/05 by Johnson & Johnson, which said it's in discussions with the Food and Drug Administration and regulators in Europe and Canada.

The trials, involved approximately 2,000 patients in 16 countries. were looking if Reminyl could be used to treat mild cognitive impairment, a form of memory loss that is often associated with Alzheimer's. Reminyl is approved in 69 countries as a treatment for mild to moderate Alzheimer's but not for mild cognitive impairment. In the trials, which lasted two years, 15 patients taking Reminyl died compared with 5 taking the placebo.

The announcement comes at a time of heightened concern over the safety of widely used drugs after the withdrawal from the market of Merck's pain reliever, Vioxx, which studies indicated posed an increased risk of heart attacks and strokes. Johnson & Johnson responded by saying that the overall number of deaths in the trials was low for the elderly population in the trial and that the incidence of serious side effects was the same for patients getting the drug and the placebo. Also, it said, the investigators in the trials had not thought the drug caused any of the deaths.

Reminyl was approved on the basis of six-month studies but the mild cognitive impairment trials lasted two years, increasing their chances of detecting side effects. Nevertheless, the Johnson & Johnson analysis said the excess of deaths in the mild cognitive impairment trials was evident by six months, while no such excess was seen in the Alzheimer's trials.

Reminyl was developed with Shire Pharmaceuticals of Britain. Sales for Johnson & Johnson are estimated at about $200 million a year. Public Citizen, the watchdog group, recommends against using Reminyl or other drugs in its class, saying they have minimal benefit and the effectiveness and safety of taking them longer than six months is not known, according to Sidney Wolfe, director of health research.

Legal Help For Victims Affected By Reminyl

If you or a loved one took Reminyl and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


ReminylRSS Feed

Pharmacies Ignore Pullout Order, Sell Harmful Ophthalmic Solution

Jun 26, 2006 |
Despite the announcement a month ago by the manufacturers of a highly harmful ophthalmic solution that they were recalling the product, the item is still available in pharmacies across Jeddah. Bausch & Lomb, the manufacturers of the contact lens clearing solution ReNu with MoistureLoc, announced their decision to call back the product from markets worldwide due to a high rate of eye infection associated with it. The Saudi Ministry of Health also issued a precautionary note around the same...

Reminyl (galantamine) Precautions due to Deaths Reported in Clinical Trials

Apr 1, 2005 |
Ortho-McNeil Neurologics modified the PRECAUTIONS section of the Prescribing Information for Reminyl, approved only for the treatment of mild to moderate Alzheimer's Disease. The changes provide new safety information regarding the results of two randomized, placebo-controlled trials of 2 years duration in subjects with mild cognitive impairment(MCI). A total of 13 subjects on REMINYL (n=1026) and 1 subject on placebo (n=1022) died. The deaths were due to various causes which could be expected...

Trials Show Higher Death Rate Among Some Test Subjects Using Reminyl

Jan 22, 2005 | AP
Patients taking Alzheimer's drug Reminyl in a test for another use had higher death rates than those taking a placebo, Johnson & Johnson Pharmaceutical Research & Development LLC announced Friday. The patients had mild cognitive impairment, and the J&J company is no longer pursuing Reminyl as a treatment for the condition and has not submitted any applications for such use, spokeswoman Carol Goodrich said. Reminyl was approved in 2001 as a treatment for mild to moderate Alzheimer's disease. The...

More Reminyl News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo